Once-Weekly Insulin Added To Novo Nordisk’s Clinical Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo Nordisk is evaluating new long-acting and quick-acting insulins in clinical trials as competitive pressure looks set to intensify in 2013 for its market-leading GLP-1 agonist, Victoza.